Valuation: Acelyrin, Inc.

Market Cap 229M 199M 188M 170M 319M 21.98B 321M 2.24B 866M 11.15B 861M 842M 35.54B P/E 2023
-1.37x
P/E 2024 -1.26x
Enterprise Value -211M -183M -173M -157M -295M -20.28B -296M -2.07B -799M -10.29B -794M -777M -32.79B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
84.72%
Yield 2023 *
-
Yield 2024 -
3 years 1.84
Extreme 1.845
11.23
5 years 1.84
Extreme 1.845
29.88
10 years 1.84
Extreme 1.845
29.88
Date Insider Type Main position Quantity % Market Cap. Importance
21/05/25 Issuer sale

Director

285,851 0.2839%
21/05/25 Issuer sale

Director

297,608 0.2955%
21/05/25 Issuer sale

Director

9,966,130 9.8966%
Change 5-day change 1-year change 3-year change Capi.($)
+1.79%-.--%-.--%-80.05% 229M
+0.66%+0.87%+47.39%+97.63% 69.18B
-1.19%-1.99%+33.01%+73.08% 62B
+2.22%-1.85%-14.36%+360.65% 26.19B
+1.46%+1.30%+28.58%+13.76% 25.75B
-0.89%-2.87%-2.09%-15.24% 24.29B
+2.84%+2.12%+24.28%-17.13% 19.84B
0.00%-14.23%+170.04%+298.75% 15.65B
-0.57%+0.12%-8.66%+825.13% 13.88B
-0.39%-5.61%-9.51%+483.04% 14.09B
Average +0.59%-1.71%+26.87%+203.96% 27.11B
Weighted average by Cap. +0.33%-0.98%+31.44%+159.69%

Financials

2023 2024
Net sales - -
Net income -382M -331M -313M -284M -532M -36.61B -535M -3.73B -1.44B -18.57B -1.43B -1.4B -59.19B -248M -215M -203M -185M -346M -23.81B -348M -2.43B -938M -12.08B -932M -912M -38.5B
Net Debt -720M -624M -590M -535M -1B -69.06B -1.01B -7.04B -2.72B -35.03B -2.7B -2.64B -112B -441M -382M -361M -328M -614M -42.27B -618M -4.31B -1.66B -21.44B -1.66B -1.62B -68.33B
Logo Acelyrin, Inc.
ACELYRIN, INC. is a late-stage clinical biopharma company. The Company is focused on providing treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The Company has two programs in late-stage clinical development. The Company’s lead product candidate, izokibep, is being evaluated in multiple immunologic indications, including hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and uveitis. The Company is also developing Lonigutamab for the treatment of thyroid eye disease (TED), as well as developing SLRN-517 in chronic urticaria. Izokibep is an inhibitor of anti-interleukin (IL)-17A in phase III development for the treatment of psoriatic arthritis, hidradenitis suppurativa and uveitis. Lonigutamab is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of TED. SLRN-517, a fully IgG1 human monoclonal antibody designed to target a distinct epitope of c-KIT.
Employees
83
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. SLRN Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!